Description
Rp2d is an investigational vaccine being studied in clinical trials for certain types of advanced colorectal cancer. It is designed to work with the immune system to target cancer cells. Specifically, it is being investigated for use in patients whose tumors are MSI-H (microsatellite instability-high) or dMMR (deficient mismatch repair). These are specific genetic characteristics found in some colorectal cancers. In trials, Rp2d is being given in combination with pembrolizumab (Keytruda®), an immunotherapy drug that blocks a protein called PD-1, which can help the immune system attack cancer cells. The vaccine is given as a series of injections (a 'prime' shot followed by 'boost' shots). The goal is to stimulate the patient's own immune system to recognize and fight the cancer.
Mechanism of Action
Rp2d is a genetic vaccine. It uses genetic material (DNA) to instruct the body's cells to produce specific proteins, called neoantigens, found on the surface of the patient's cancer cells. These neoantigens are unique to the individual's tumor. By presenting these neoantigens to the immune system, the vaccine aims to train the immune system, specifically T-cells, to recognize and destroy the cancer cells. It is being studied in combination with pembrolizumab, which enhances the immune response against cancer.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.